Switching to a two-drug HIV regimen for transgender women
Treatments studied
Part of Infections clinical trials.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a transgender woman (self-identified).
- You have been on a stable three-drug HIV regimen for at least 3 months with undetectable HIV levels.
- You have had at least two HIV tests showing undetectable levels in the past year.
- You do not have active hepatitis B or C (or untreated syphilis).
- You have no history of resistance to dolutegravir or lamivudine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial tests whether switching (or continuing) treatment with dolutegravir (DTG) plus lamivudine (3TC) works as well and is better tolerated in adults with HIV that is already controlled. It is specifically for people who have possible kidney (TDF-related) or bone side effects from their current TDF-based regimen.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.